Designing a Drug-like Candidate using Machine Learning

To design a candidate drug molecule in-silico by adjusting its molecular descriptors, and to evaluate it with a machine-learning model that predicts drug-likeness and predicted oral bioavailability, thereby understanding how AI accelerates early drug discovery.

Artificial Intelligence (AI) is the branch of computer science that builds systems able to perform tasks needing human-like reasoning. Machine Learning (ML) is a subset of AI in which a model learns patterns from data instead of being explicitly programmed, and Deep Learning is a further subset that uses multi-layered neural networks.

In early drug discovery, screening real molecules in the lab is slow and expensive. AI models are trained on thousands of known drugs and non-drugs, learning which physicochemical properties make a molecule a good oral drug. New candidate molecules can then be screened in seconds — this is called in-silico screening.

The most famous rule set is Lipinski's Rule of Five. A molecule is likely to be an orally active drug if it does not violate more than one of:

• Molecular weight (MW) ≤ 500 Da
• Lipophilicity (LogP) ≤ 5
• Hydrogen-bond donors (HBD) ≤ 5
• Hydrogen-bond acceptors (HBA) ≤ 10

Veber's rules add two absorption-related limits: topological polar surface area (TPSA) ≤ 140 Ų and rotatable bonds ≤ 10.

In this tool the AI verdict is produced by a logistic-regression classifier — one of the simplest ML models. It combines the descriptors with learned weights and passes the sum through a sigmoid function to output a probability between 0 and 1:

• A computer / tablet with a modern web browser (this virtual e-lab tool).
• The molecular-descriptor control panel (built in).
• The trained AI drug-likeness & bioavailability model (built in).
• A reference set of known drugs (provided as "starting scaffolds").
• Your lab notebook — or use the built-in report generator.

1. Go to the Formulation Workbench. Note the formulation goal.
2. Choose a starting scaffold (a known drug). Watch the molecule build itself on the synthesizer panel and read its baseline scores.
3. Adjust the six sliders (MW, LogP, HBD, HBA, TPSA, rotatable bonds). The molecule morphs live and the AI re-scores instantly. Sliders turn amber when a value breaks a rule.
4. Work toward the goal: keep the drug-likeness gauge high and push predicted bioavailability ≥ 70% with no violations. Tip: moderate LogP (about 1–3) and low TPSA (below 90 Ų) improve absorption.
5. When satisfied, click "Log this candidate" to record it in the observation table.
6. Repeat with different scaffolds and settings — log at least three candidates.
7. Go to Generate Report, write your observation and conclusion, and produce a printable report with your results.

Use this five-step method whenever a candidate fails screening. Fix the biggest problem first, then re-check the AI gauges after every change.

1. Read the diagnosis. Look at which rule checks are red and whether bioavailability is low. The red boxes tell you exactly which property is out of range.
2. Fix violations first. Bring any red property back inside its limit — MW ≤ 500, LogP ≤ 5, HBD ≤ 5, HBA ≤ 10, TPSA ≤ 140, rotatable bonds ≤ 10.
3. Tune LogP into 1–3. Too low = poor permeability, too high = poor solubility. The 1–3 window gives the best balance.
4. Drop TPSA below 90 Å². This is the single strongest lever for oral absorption. Reducing polar donors/acceptors lowers TPSA.
5. Trim size & flexibility. Lower MW toward 250–450 and keep rotatable bonds low so the molecule is compact and rigid enough to absorb well.